Advancements in Medical AI Are Improving Timely Esophageal Cancer Detection

Scientists in China recently identified an innovative system that considerably increases the rate of detection of esophageal cancer lesions. Esophageal cancer starts from the esophagus, which ferries food from the throat to the stomach.

Early detection of this particular cancer is crucial as rates of survival considerably increase when the illness is identified and treated in its early stages. Unfortunately, this cancer is often diagnosed in its later stages when patients begin presenting with symptoms, which makes treatment more difficult.

So, how does artificial intelligence improve esophageal cancer detection?

Artificial intelligence analyzes endoscopic images using advanced algorithms to identify lesions that may show the presence of cancer. This allows for earlier and more accurate detection that is possible with a human, especially those who have limited experience with this disease.

The use of this technology is expected to significantly reduce the frequency of misdiagnoses.

Other advantages of artificial intelligence in the early detection of esophageal cancer include consistency, with the model offering consistent evaluations. This is a slight change from human evaluations, which can vary due to subjective bias or fatigue. The system is also fast because it can analyze data faster than healthcare professionals. This expedites the diagnostic process.

This breakthrough isn’t the first in China’s healthcare sector either.

In 2023, the country developed an AI model that could identify early-stage pancreatic cancer. The model uses X-ray imagery to identify this fatal disease, which showcases the potential of artificial intelligence in transforming how cancer is diagnosed as well as patient outcomes.

Despite the positives, there are challenges associated with the integration of artificial intelligence into the health sector.

A good example of this would be ensuring the reliability and accuracy of artificial intelligence systems and addressing security and privacy concerns for artificial intelligence-based diagnostic errors. Additionally, many healthcare professionals are reluctant to rely on artificial intelligence, with many preferring instead to do their diagnoses themselves.

The disadvantages of artificial intelligence in the early detection of esophageal cancer include cost, as the development as well as implementation of advanced artificial-intelligence technologies can be expensive. It is also expected that overreliance on artificial intelligence may lead to the loss of traditional diagnostic skills among healthcare professionals.

Researchers believe that the use of artificial intelligence in medical diagnostics is a frontier with potential that could greatly improve how illnesses are identified and treated. It is expected that as artificial intelligence systems continue evolving, accurate detection of life-threatening illnesses could become a reality.

As advances are being pushed on the AI front, other entities such as Astrotech Corp. (NASDAQ: ASTC) are working to avail medical diagnostic instruments, which can be leveraged by experienced personnel to diagnose various ailments in the absence of affordable and widely available AI solutions.

NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN